News List
Tehran, April 16,2025 – Razi Vaccine & Serum Research Institute, in collaboration with the Pasteur Institute of Iran, Ministry of Defense, and Foreign Ministry, organized a one-day training workshop titled "The Joint Training Program on the Biological Weapons Convention" at the Ministry of Defense.
Tehran, Iran – April 14-15, 2025 –The World Health Organization (WHO) and Riskren have launched a two-day online training program aimed at raising awareness of GAPIV, titled “GAPIV RCA/CAPA.”
Karaj, April 10, 2025— Dr. Masoud Pezeshkian, President of Iran, visited Razi Vaccine and Serum Research Institute, accompanied by a government delegation, to assess the institute's scientific capabilities and discuss the establishment of the nation's first technology tower. The visit, which included tours of various facilities within the institute, featured discussions alongside prominent figures such as Dr. Gholamreza Nouri Ghezeljeh, Minister of Agriculture-Jahad, and Dr. Gholamreza Golmohammadi, Deputy Minister and President of the Agricultural Research, Education, and Extension Organization. Together, they engaged with senior officials at Razi to delve into the institute's research potential and the proposed technology tower project.
On Tuesday, April 8, Dr. Masoud Pezeshkian, President of the Islamic Republic of Iran, participated the board of trustees meeting of Razi Vaccine & Serum Research Institute.
On April 8, 2025, Razi Institute participated in the meeting organized by the Iran Food and Drug Administration (FDA) that focused on enhancing regulatory systems for biological medicines and blood products. This event brought together prominent global health officials, including Dr. Rogerio Paulo Pinto De Sá Gaspar, Director of the Regulation & Prequalification Department at WHO HQ; Dr. Adham Rashad Smail Abdel Moneim, WHO EMRO Director; and Dr. Jaffar Hussain, WHO representative for Iran.
Tehran, Iran – April 7-8, 2025 – WHO and Riskren have piloted a 2-day online training on GAPIV awareness for PV1 PEFs titled “GAPIV Document Preparation and Review Training for PEFs.” This training aims to help PEFs gain fundamental understanding of GAPIV requirements and also provide them a platform to share their knowledge and experiences through interactive exercises and discussions. The training will focus on several key objectives including Supporting participants' understanding of the document review process, ensuring GAP documentation is well-structured and comprehensive, discussing documents that may be requested and reviewed during a GAP audit, using a sample document form, providing a forum to discuss potential challenges and solutions related to document compilation and review.
The Ministry of Health has officially recognized the Razi Vaccine and Serum Research Institute for its pivotal role in eliminating measles and rubella from the country.
On Saturday, March 15, the Razi Institute hosted a session to present the final report of the “International Online Conference on Antivenins and Venomous Animals”, organized in collaboration with the World Health Organization and took place from February 17-18. Attendees included Dr. Ali Es-haghi, Director General of the Razi Institute, Dr. Soheila Moradi Bidhendi, Deputy of Research and Technology, and members of the conference committee.
In a pivotal step toward enhancing international collaboration, Razi Institute took part in the inaugural brainstorming session organized by the Deputy Directorship of Legal and International Affairs of the Ministry of Foreign Affairs. The meeting was hosted by Dr. Kazem Gharibabadi, Deputy Foreign Minister for Legal and International Affairs, and included the participation of seventy officials from relevant organizations.
TEHRAN, March 9, 2025– Razi Vaccine & Serum Research Institute (RVSRI) is proactively elevating the quality and global accessibility of its snake antivenom immunoglobulin products by integrating World Health Organization (WHO) guidelines into its production protocols. Following participation in the "WHO Workshop on Risk-Benefit Assessment of Snake Antivenom Immunoglobulin Products" (Dubai, December 3-4, 2024), RVSRI organized a technology and experience transfer seminar on Sunday, March 9, 2025, this seminar aimed to transfer the information and knowledge acquired during the workshop to the designated officers in the institute responsible for Quality Assurance, Production, Quality Control and Medical Affairs.
Dr. Morteza Taghizadeh Taranabi, a faculty member at Razi Vaccine and Serum Research Institute, announced the institute's plans to identify high-risk areas in the Middle East and secure antivenom supplies in collaboration with international organizations.
Razi Vaccine & Serum Research Institute is enhancing its scientific standing on the global stage through international conferences aimed at fostering research and laboratory collaborations. Dr. Rainak Ghaderi, Head of Academic Relations and International Affairs, emphasized this initiative during the recent International Online Conference on Venomous Animals and Antivenom, hosted by Razi Institute in collaboration with the World Health Organization (WHO).
Razi Vaccine & Serum Research Institute has significantly enhanced the quality control of therapeutic serums, establishing itself as a reference point for services across the country. Dr. Sina Soleimani, Head of Quality Control for Biological Products at the institute, announced that Razi Institute is equipped with advanced technology and specialized laboratories to ensure the highest standards in serum quality.
At the International Online Conference on Venomous Animals and Antivenom Dr. Abbas Zare Mirakabadi, head of the Venomous Animals Department, emphasized the conference's focus on antivenoms and toxins, presenting a valuable opportunity to strengthen scientific collaboration, particularly with Razi Institute as a leading research hub.
Razi Vaccine & Serum Research Institute is initiating a comprehensive plan to enhance quality and expand its international markets. Dr. Majid Tabianian, Head of Serum Purification and Therapeutic Serum Formulation, announced this initiative during the recent International Conference on Venomous Animals and Antivenom.
In a statement from Razi Institute's Public Relations department, Dr. Morteza Akbarian directorate in charge and advisor to the Director General of Razi Vaccine and Serum Research Institute, emphasized the institute's crucial role in therapeutic serum production. He noted that this initiative was established in Iran by the late Dr. Latifi within the institute’s venomous animal department. According to numerous international specialists, the antivenoms produced by Razi are regarded as some of the highest quality products available globally.
Razi Vaccine & Serum Research Institute is setting its sights on obtaining a World Health Organization (WHO) collaborating laboratory license to enhance research in the field of venom and antivenom, according to Dr. Soheila Moradi Bidhendi, the institute's Deputy for Research and Technology. This initiative aims to expand international collaborations dedicated to preserving human health.
Dr. Najmeh Motamed, The executive secretary of the International Online Conference on Venomous Animals and Antivenom has highlighted the profound impact of Razi Vaccine & Serum Research Institute's antivenoms, which have saved countless lives across Iran and the Middle East. This year, RVSRI unveiled a new antivenom specifically developed for venomous snakes found in Sistan and Baluchestan Province.
